Meiji Holdings Co Ltd: Segment Analysis

Meiji Holdings Co Ltd (Meiji) develops, manufactures and distributes dairy products, confectioneries, nutrition and pharmaceutical products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Meiji has undertaken a wide range of research and development initiatives across various sectors, including food, pharmaceuticals, and animal health. In the food sector, the company has focused on developing new yogurt products, expanding its milk and beverage offerings, and launching innovative chocolate and gummy products. The company has also made significant strides in high-nutrition foods and food solutions for commercial use. In the pharmaceutical sector, Meiji Holdings is advancing its position in infectious diseases, hematological cancers, and generic drugs, with notable progress in vaccine development and biopharmaceuticals. The company is also actively involved in animal health, with approvals and trials for various veterinary drugs and vaccines. Additionally, Meiji Holdings is leveraging its strengths in both "medicine" and "food" to create new business opportunities and technologies through its Wellness Science Lab. The R&D activities of Meiji are managed by several units, including the Wellness Science Lab, which focuses on integrating the company's strengths in "medicine" and "food" to create new business opportunities and technologies. KM Biologics Co., Ltd. handles research and development, manufacturing, and sales of biopharmaceuticals, including human vaccines and plasma-derived products. Meiji Animal Health Co., Ltd. is responsible for the development of veterinary drugs and vaccines. In FY2026, the company incurred expenses of JPY26,670 million on R&D, which as a percentage of revenue, stood at 3.4%.